Clinical trials
Uterine Cervical Neoplasms trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 3 |
| Merck Sharp & Dohme LLC | 3 |
| Affidea Nu-med Center of Oncological DIagnostics and Therapy | 2 |
| Agenus Inc. | 2 |
| Maria Sklodowska-Curie National Research Institute of Oncology | 2 |
| Medical University of Silesia | 2 |
| Amgen | 1 |
| Arcus Biosciences, Inc. | 1 |
| Ascendis Pharma Oncology Division A/S | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Uterine Cervical Neoplasms | 28 |
| Ovarian Neoplasms | 7 |
| Endometrial Neoplasms | 6 |
| Squamous Cell Carcinoma of Head and Neck | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Stomach Neoplasms | 4 |
| Triple Negative Breast Neoplasms | 4 |
| Carcinoma, Hepatocellular | 3 |
| Cholangiocarcinoma | 3 |
| Esophageal Neoplasms | 3 |
Trials
Showing 26 to 28 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.